Ampio Pharmaceuticals Inc (AMPE)

[conix]

AMPIO PHARMACEUTICALS INVESTMENT HIGHLIGHTS

*Osteoarthritis is an incurable, progressive, chronic, degenerative and inflammatory disease.

*CDC estimates that it affects over 30 million adults in the U.S./ Hundreds of Millions Worldwide

*Degenerative Arthritis is the most common cause of knee pain - probability is over 50% getting it.

*Standard of Care is: steroid injection; total knee replacement; other opiods

*Company's drug candidate - "Ampion" - seeks to address this in severe knee pain(OAK)

*Has agreement with FDA on a SPA on the design of pivotal Phase III trial

*Company has in-house manufacturing capabilities for 'Ampion'

*Trial seeks 1000 patients with primary endpoint of pain and function

Currently, over 280 have enrolled in the study and over half have received Ampion

*Trial readout in 2020.

*'Ampion' Method of Action has potential for other inflammatory indications/conditions in human body

Ticker: AMPE

H-L:$0.36 - $1.31

Market Cap:$ 65 Million

About Ampio Pharmaceuticals:

Ampio Pharmaceuticals is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. We are developing compounds that serve significant medical needs in osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases through an innovative discovery and development platform.

www.ampiopharma.com